<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1951">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733833</url>
  </required_header>
  <id_info>
    <org_study_id>VB-201-019</org_study_id>
    <nct_id>NCT04733833</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19</brief_title>
  <official_title>A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Biogenics Ltd. operating as VBL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Biogenics Ltd. operating as VBL Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral&#xD;
      preparation of VB-201 in patients with severe COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of VB-201</measure>
    <time_frame>Subjects will participate in the study for approximately 7 weeks: up to 1 day for screening and establishment of baseline, followed by 14 days of treatment and a follow-up visit 4 weeks after last dose of study medication.</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (Time frame: Adverse events will be collected from the time the informed consent is signed through 28 days after the subject's last dose. All adverse events that are ongoing at the time of completion/discontinuation will be followed until resolution or the event is chronic or stable in the opinion of the investigator).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Severe COVID-19</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VB-201 + standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB-201 + Standard of care</intervention_name>
    <description>Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and approved informed consent before initiation of protocol-specified&#xD;
             procedures;&#xD;
&#xD;
          2. Male or female subjects, ≥18 to ≤80 years of age with COVID-19&#xD;
&#xD;
          3. SARS-2-CoV-2 infection confirmed by PCR in the last 8 days&#xD;
&#xD;
          4. Hospitalized&#xD;
&#xD;
          5. Symptoms of Severe COVID-19 as demonstrated by one of the following:&#xD;
&#xD;
               -  Respiratory frequency &gt;30 breaths per minute&#xD;
&#xD;
               -  SpO2 &lt;94% on room air at sea level&#xD;
&#xD;
               -  Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen&#xD;
                  (PaO2/FiO2) &lt;300 mmHg&#xD;
&#xD;
               -  lung infiltrates &gt;50%&#xD;
&#xD;
          6. For a female subject; either:&#xD;
&#xD;
               -  subject is of non-childbearing potential, defined as: menopause with amenorrhea&#xD;
                  &gt;1 years, hysterectomy, or bilateral oopherectomy or&#xD;
&#xD;
               -  agrees to continue to use highly effective methods of birth control defined as&#xD;
                  those alone or in combination that result in a low failure rate (&lt;1%) when used&#xD;
                  consistently and correctly throughout the study and for at least one month&#xD;
                  following treatment termination and have a negative pregnancy test at screening&#xD;
                  and before the first dose of study drug; Males must use at least one method of&#xD;
                  contraception (e.g. condom) throughout the study and for 90 days following the&#xD;
                  last dose of study drug;&#xD;
&#xD;
          7. In the opinion of the investigator, the subject will be compliant and have a high&#xD;
             probability of completing the study and all required procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of critical COVID-19 based on any of the following&#xD;
&#xD;
               -  Admission to ICU&#xD;
&#xD;
               -  Assisted ventilation (invasive or non-invasive)&#xD;
&#xD;
               -  ECMO or hemofiltration required&#xD;
&#xD;
               -  ARDS&#xD;
&#xD;
               -  Shock&#xD;
&#xD;
               -  Acute Cardiac Failure&#xD;
&#xD;
          2. Dementia&#xD;
&#xD;
          3. Bacterial co-infection&#xD;
&#xD;
          4. Co-infection with other common viral pneumonias (e.g. Influenza)&#xD;
&#xD;
          5. Participation in another interventional clinical trial or intention to participate in&#xD;
             another interventional study during the course of this study;&#xD;
&#xD;
          6. In the opinion of the investigator, unlikely to survive for at least 48 hours from&#xD;
             screening or anticipate mechanical ventilation within 48 hours&#xD;
&#xD;
          7. Unable to take oral medication&#xD;
&#xD;
          8. History of gastrointestinal illness that may cause nausea and vomiting&#xD;
&#xD;
          9. Subjects with any laboratory test at screening that common medical practice would deem&#xD;
             as significantly abnormal. For example:&#xD;
&#xD;
               -  Alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase&#xD;
                  &gt;5.0 times the upper limit of normal (ULN) or&#xD;
&#xD;
               -  Creatinine clearance &lt;30 mL/min&#xD;
&#xD;
         10. The subject has a known allergy or sensitivity to the study treatment or to any of the&#xD;
             excipients contained in the study drug formulation (see list of ingredients in the&#xD;
             Investigator's Brochure);&#xD;
&#xD;
         11. Female subject with a positive pregnancy test or nursing, or planning a pregnancy&#xD;
             during the course of the study;&#xD;
&#xD;
         12. Unwilling or unable to comply with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Halperin</last_name>
      <phone>+972-3-5303500</phone>
      <email>Rebecca.Halperin@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Galia Rahav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Severe</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

